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ABSTRACT: We assess the stability of two previously suggested binding modes for the
neuropeptide orexin-A in the OX2 receptor through extensive molecular dynamics
simulations. As the activation determinants of the receptor remain unknown, we simulated
an unliganded receptor and two small-molecular ligands, the antagonist suvorexant and the
agonist Nag26 for comparison. Each system was simulated in pure POPC membrane as well
as in the 25% cholesterol−POPC membrane. In total, we carried out 36 μs of simulations.
Through this set of simulations, we report a stable binding mode for the C-terminus of
orexin-A. In addition, we suggest interactions that would promote orexin receptor activation,
as well as others that would stabilize the inactive state.
■ INTRODUCTION
Orexin System. Peptide Binding. The orexin receptors
are key regulators in several neurological processes. The main
physiological role of the orexinergic system is the regulation of
sleep, and it also plays a role in energy homeostasis and the
reward system.1 Orexin receptors are prominent drug targets
for novel hypnotics,2,3 and hopefully, in the future, narcolepsy
could be alleviated through orexin receptor activation.4,5
Orexin receptors are also putative targets for cancer treatment,
as orexinergic signaling directs certain cancer cell lines to
apoptosis.6 However, the treatment of both narcolepsy and
cancer through orexin receptors would require agonistic
ligands, whereas the pharmaceutical industry has concentrated
on antagonists. A few potent small-molecular agonists have
been reported and characterized,7−9 but the poor under-
standing of the receptor activation determinants hampers the
search for new agonists.
The orexinergic system comprises two peptide ligands,
orexin-A and -B, and two G protein-coupled receptors
(GPCR) OX1 and OX2.
10 In aqueous solution, the orexin
peptides adopt conformations comprising helical segments I
and II (and III for orexin-A), with a structural hinge motif
between the helices I and II (Figure 1).11−13 Orexin-B, which
is a linear 28-amino-acid amidated peptide, shows a 90° bend
between the helices I and II, at N20−A22, i.e., 1.5 turns from
the C-terminal. Orexin-A, a 33-amino-acid amidated peptide
with two intramolecular disulfide bridges, is often observed
with a similar bend at A23−N25, half a turn further from the
C-terminus, resulting in bending in the opposite direction in
comparison to orexin-B (Figure 1). In addition to the bent
conformations, orexin-A appears in some NMR-models in a
straight α-helical conformation, except for the disulfide-bridge-
stabilized hook at the N-terminus. For orexin-B, such
conformation has not been reported.
Site-directed mutagenesis (SDM) on both receptor subtypes
and both peptides has highlighted several key residues for
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Figure 1. Orexin peptides. Sequences are colored consistently with
the figures. X: Pyroglutamoyl; lines denote disulfide bonds. For
orexin-B (top right), one conformation has been published,13 while
for orexin-A, three conformations have been observed.11,12
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peptide−receptor interaction.14−20 The most notable observa-
tions is that the C-terminus of both orexin peptides is vital for
bioactivity, whereas the N-terminus can be mutated or even
deleted without the loss of activity, which has given rise to the
assumption that the C-terminus enters the canonical class A
GPCR binding cavity. With this information, molecular
modelers have provided few suggestions on the binding
mode for the orexin peptides,21,22 with the assumption that the
C-terminus binds in the α-helical conformation observed in
solution, but validation of these suggestions has been
challenging. Recently, we suggested that orexin peptides
locked in an α-helical conformation can indeed activate the
orexin receptors,23 but as the method included an introduction
of a bulky hydrocarbon linker between two helical turns and
severely impaired the peptide’s potency, no firm conclusions
could be drawn.
GPCR Activation. Simulations of GPCRs. GPCR
activation is a process where ligand binding stabilizes a
receptor conformation that allows for G protein (or other
effector protein) binding, activation and downstream signal-
ing.24 As GPCR ligands differ greatly, also the key interactions
at the binding site must differ. Among the class A GPCRs, the
activation cascade that links events at the binding site with the
intracellular G protein binding site appears to converge into
defined interaction patterns,25 and large-scale movements such
as the outswing of the TM6 (the sixth transmembrane helix),
which opens up the G protein binding site.26
Molecular dynamics (MD) simulations have shed light on
different parts of the receptor function, such as ligand binding,
receptor transitions both between and within active and
inactive states, and allosteric modulation.27 The opening of the
G protein binding site has not been observed in classical MD
simulations reaching up to tens of microseconds, but the
reverse event has been reported.28 In contrast, the binding site
and the so-called core triad can adopt activelike conformations
within a microsecond-scale simulation.28
In the present study, we set out to simulate the OX2 receptor
with two previously reported alternative orexin-A binding
modes,21 a small molecular agonist Nag267 and a small
molecular antagonist suvorexant.2 In addition, we simulated an
unliganded receptor. Our main point of interest was the ligand
binding interactions and their stability. As our simulations did
not include G proteins or mimetics thereof, we anticipated that
the transition of the receptor into its active state was likely
beyond our reach, but we hoped to observe such differences
between the ligands that could indicate key interactions for
agonism.
■ METHODS
Overview. We carried out and analyzed a total of 36 μs of
molecular dynamics simulations. We simulated OX2 receptor
without a ligand, with small molecules suvorexant and Nag26
and with two alternative binding modes of orexin-A. Each
simulation was run both in a pure POPC (1-palmitoyl-2-
oleoylphosphatidylcholine) membrane and in a POPC−cho-
lesterol (25%) membrane for 3 μs. For Nag26 and orexin-A
simulations, we also produced 1 μs replicas. The simulation
conditions are summarized in the Table 1, and the simulations
are referred to by their numbers thereafter. For the system
setup and analysis we employed Gromacs 5.1,29 and for the
MD simulations Gromacs 4.6.7.30
Amino Acid Numbering. For clarity, we use one-letter
amino acid codes for the orexin-A, and three-letter codes for
the OX2 receptor. For the receptor, we use the GPCRdb
numbering scheme,31 in which the most conserved amino acid
in each transmembrane helix is denoted Nx50, where N is the
number of the respective helix. Amino acids up- and
downstream are numbered consecutively based on their
overlap with an ideal α helix; if a residue is “missing”, the
corresponding number is skipped, and in the case of bulges, the
residue furthest from the helical axis is denoted NxYY1, where
NxYY is the number for the previous residue.
System Setup. The OX2 Receptor. The OX2 receptor
crystal32 (PDB id: 4S0V) is missing the N-terminus upstream
of Pro50, residues 160−163 (the second intracellular loop,
ICL2), 198−202 (top of the hairpin in the second extracellular
loop, ECL2), 255−293 (ICL3), 336−337 (ECL3), and the C-
terminus downstream of Cys381. Few side-chain atoms are
also missing near the unresolved sections. To fill these gaps, we
used Modeller 9.1433 with default settings to build 30
homology models of the human OX2 (residues 50−254 and
294−381) using the crystal structure 4S0V as a template, and
selected the model with the lowest RMSD in comparison to
the template. We left out the receptor termini and the ICL3
since long stretches such as these do not produce reliable
models without suitable templates, which were not available at
the time. We set all arginine, lysine, glutamic acid, and aspartic
acid residues as charged, except for the Asp1002x50, which we
set to be protonated.34 We allowed Gromacs to decide the
protonation states for histidine residues based on the optimal
hydrogen bonding conformation with default settings.
Peptide Docking. Orexin-A2−33 in the straight α-helical
conformation11 was docked to the receptor model with
ZDOCK35 and docking poses were refined with RDOCK36
via Discovery Studio 4.5.37 As pyroglutamate is not para-
metrized in these docking algorithms, we were forced to omit
the first residue. It was added manually prior to simulation.
From top-scoring docking poses, we selected manually two
poses that were close matches to our previously published
binding modes,21 which were named the TM5-mode and the
TM7-mode based on the orientation of H26.
Small Molecule Placement. Suvorexant was copied from
the OX2 crystal structure 4S0V.
32 Nag26 was docked to the
crystal structure as described previously.38 In short, Nag26 was
docked with Glide induced-fit protocol, retaining the binding
site water molecules. Shape and interaction similarities to
Table 1. Molecular Dynamics Simulations
sim. ligand membrane length (μs)
1 orexin-A, TM5 POPC 3
2 orexin-A, TM5 POPC 1
3 orexin-A, TM5 POPC−CHOL 3
4 orexin-A, TM5 POPC−CHOL 1
5 orexin-A, TM7 POPC 3
6 orexin-A, TM7 POPC 1
7 orexin-A, TM7 POPC−CHOL 3
8 orexin-A, TM7 POPC−CHOL 1
9 suvorexant POPC 3
10 suvorexant POPC−CHOL 3
11 Nag26 POPC 3
12 Nag26 POPC 1
13 Nag26 POPC−CHOL 3
14 Nag26 POPC−CHOL 1
15 none POPC 3
16 none POPC−CHOL 3
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suvorexant directed the pose selection. The selected pose (but
not the water molecules) was then copied into the binding
cavity of the homology model with no further refinement.
Membrane. We employed CHARMM-GUI39−42 to gen-
erate two hexagonal membranes solvated in TIP3P43 water to
result in a 12 nm total height. We used a pure POPC
membrane of 150 lipids per leaflet, and a POPC + CHOL
(25%) membrane of 126 + 42 lipids per leaflet. The membrane
size was selected to ensure at least 50 Å between the periodic
images of the protein in the membrane plane, and 25 Å in the
direction perpendicular to the membrane. Both membrane
models employed here are simplified representations of reality.
For computational feasibility, we selected only one phospho-
lipid for the study. POPC membranes are frequently used in
MD simulations as the lipid is commonly present in
biomembranes.44 The comparison of simulations, especially
in the field of GPCRs, is facilitated by employing membranes
similar to other studies.28,45−50 While most MD simulations
with GPCRs employ single-component membranes, we
additionally replicated all simulations with cholesterol-contain-
ing membranes to probe for the effects of the membrane
composition. Cholesterol is known to be present in the cellular
membrane, and its effects on the membrane thickness and
packing are clear.51−54 Also, several interaction sites for
cholesterol have been mapped onto the membrane-facing
interface of GPCRs.55
As the starting positions for the cholesterol in contact with
the receptor can have a significant impact on their distribution
through the simulation, we carried out coarse-grained
MARTINI56 simulations to define suitable starting locations.
We used CHARMM-GUI39−42,57 to embed the OX2 receptor
in POPC−cholesterol bilayers with 10%, 25% or 50% of
cholesterol, and to derive necessary topologies for the
simulation. All systems were energy-minimized for 5000
steps and subsequently equilibrated for 100 ns (NVE
ensemble). Then, each system was simulated for 10 μs in
triplicate under NPT conditions. A time step of 20 fs was used
in the simulations. Temperature of 310 K and pressure of 1.0
bar were maintained with V-rescale thermostat and Berendsen
barostat with coupling times of 1.0 ps. Long-range electro-
statics were calculated with the reaction field method and the
van der Waals interaction was cut off at 1.1 nm. All backbone
atoms of the receptor were position restrained with a force
constant of 1000 kJ/mol × nm2. The first 3 μs of each
simulation were treated as equilibration, and the final 7 μs were
subjected to analysis of cholesterol density around the protein.
This revealed 8 sites for cholesterol molecules, and 15 sites for
POPC molecules. These were back-mapped to an all-atom
system.
Construction of Simulation Systems. We inserted the
receptor complexes into the membranes with the Gromacs tool
membed with default settings except for a 0.1 resize factor in
the xy-dimension. To the POPC membrane, the protein
complex was embedded as such; this resulted in a deletion of 3
+ 3 POPC molecules, except for the peptide simulations,
where the intracellular leaflet lost an additional lipid. For the
POPC−cholesterol membrane, we first combined the receptor
with the lipids identified by the coarse-grained simulation.
Then, to ensure a symmetrical membrane with the intended
25% cholesterol content, we selected manually a suitable
location for the insertion into the generated membrane and
created a circular hole by deleting 18 POPC molecules per
leaflet and 6 + 4 cholesterol molecules from extra- and
intracellular leaflets respectively (as 5 out of 8 identified
cholesterols were on the extracellular leaflet). The receptor and
the close lipids were then inserted into the pregenerated hole.
In each system, we added NaCl to neutralize the charge for
the receptor complex and to reach a salt concentration of 100
mmol/L. The resulting systems contained 293−294 POPC
lipids or 246 POPC + 82 CHOL lipids, and ∼25 000 water
molecules in addition to necessary ions and the receptor
complex.
Force Field and Protocol. We used Amber99sb-ildn force
field58 together with Slipids59 parameters for POPC and
cholesterol. We added parameters for pyroglutamate manually,
and used atom charges from TINKER60 parameters.
Suvorexant was parametrized with Antechamber,61 with
Gaussian62-derived RESP partial charges. Nag26 parameters
were combined from Amber99sb-ildn (most bond and angle
parameters), OPSL-AA63 (bonds and angles whenever native
Amber parameters were unavailable, and torsions for the
sulfonamide) and Antechamber (torsions excluding the
sulfonamide, AM1-BCC charges64). The topologies for the
small molecules are available as part of the Supporting
Information.
All simulations were run under periodic boundary
conditions in hexagonal prism-shaped boxes. For all simu-
lations, the time step was 2 fs, center-of-mass motion was
removed every 10 steps for membrane−protein−ligand
complex and solvent separately, and Verlet pair-list was
updated every 20 steps. Temperature was kept at 310 K with
Nose−Hoover thermostat separately for membrane, solvent
and the protein complex, and pressure of 1 bar was maintained
independently for z- and xy-dimensions with semi-isotropic
Parrinnello−Rahman barostat. Short-range electrostatics and
van der Waals forces were cut off at 1 nm with long-range
dispersion corrections for energy and pressure. PME was used
for long-range electrostatics with cubic interpolation and
Fourier spacing of 0.12 nm. LINCS constraints were used with
all bonds.
Equilibration and Production. We used an equilibration
scheme inspired by a previously presented work.65 Each
simulation was equilibrated in seven 10 ns phases; in the first
phase we imposed a 1000 kJ/mol restraint on protein and
ligand heavy atoms, as well as on cholesterol heavy atoms for
the simulations in the cholesterol-containing membrane.
Through phases 2−5, we tapered off the heavy atom restraints
with 200 kJ/mol intervals, except for the cholesterols, where
the restraint was removed after phase 1. At phase 6, the 200
kJ/mol restraint was applied to all protein and peptide Cα, as
well as to all heavy atoms in the small molecular ligands. At
phase 7, the restraint was lifted from those α carbons that
reside in the receptor loops. In addition to visual examination
of the receptor, ligand and membrane, we monitored the
equilibration through the stabilization of potential energy,
simulation box vectors and receptor Cα-RMSD.
The equilibration was followed by 3 μs production runs. For
the Nag26 and orexin-A simulations in both membranes, we
started additional 1 μs replicas from the equilibrated systems.
Analysis. For analysis, each trajectory was aligned based on
the receptor Cα with the Gromacs flag progressive; i.e., each
frame was aligned to the previous frame to create continuous
motions. Analysis was carried out on these full trajectories,
except for the analysis involving water and calculation of the
preferred locations for cholesterol around the receptor. For
these, trimmed trajectories with frames every 3 ns were used.
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The analysis of membrane thickness and area per lipid was
carried out on unaligned coordinates of the final frame, as the
receptor-based alignment tends to twist the membrane slightly
out of the xy-plane.
The analysis of receptor and its interactions was conducted
with Gromacs utilities in combination with VMD66 and
Matlab.67 RMSD for protein and peptide was measured from
the α carbons, and for the small molecules from the heavy
atoms (i.e., non-hydrogen). We refer to RMSD as “external”,
when the alignment was based on the receptor Cα, and
“internal” when the alignment considered only the ligand Cα
(peptides) or heavy atoms (small molecules). Thus, external
RMSD contains ligand translation, rotation and conforma-
tional changes, whereas internal RMSD describes only the
conformational stability. Interactions were mapped residuewise
(or by atom groups in small molecules) with gmx mindist with
a cutoff of 4 Å, disregarding hydrogens, and hydrogen bonds
with the tool gmx hbond with default settings. Pairwise
interaction energies were extracted with gmx enemat. Water-
bridged hydrogen bonds were scanned with an in-house script
by framewise inspection of multiple hydrogen-bonding
partners to a single water molecule.
Stable water molecule locations, as well as preferred
locations for cholesterol were mapped with VMD Volmap as
density with default settings. Cholesterol density across the
membrane was mapped using the gmx densmap with grid size
of 1 Å. For the density analysis, we aligned the trajectories on
the protein, but allowed rotation only around the z-axis to
prevent the membrane from tilting, as this would have
hindered the separated analysis of the membrane leaflets.
Order parameters for the POPC lipids were calculated with
gmx order, and the double bond was treated as described by
Pluhackova et al.68 The area per lipid and bilayer thickness
were calculated with GridMAT-MD.69 For the analysis, the
simulation box was surrounded by periodic images in the xy-
plane, while calculations included only the lipids from the
original box. The average membrane thickness was estimated
as the area-weighted mean of the headgroup P−P distance at
individual lipids.
∑= ×
−
Z
A
A
thickness
Z: head group P P distance normal to the membrane plane
i
i
total
■ RESULTS AND DISCUSSION
Membrane. First, we analyzed the membranes to verify
that our simulations replicate the expected membrane
properties. At the end of the simulations, the pure POPC
membranes showed an average area per lipid (APL) of 60.9 ±
0.8 Å2, and membrane thickness of 36.9 ± 0.4 Å (see
Supporting Information, Table S1). These values are in line
with experimental data.51−54 The unsymmetrical insertion of
some peptide−receptor complexes did not result in marked
differences in APL. The cholesterol containing membranes
showed clear effects of cholesterol condensing with POPC
APL of 51.1 ± 0.6 Å2 and membrane thickness of 41.4 ± 0.5 Å.
Cholesterol APL was 37.5 ± 0.9 Å2. The ordering parameters
of the POPC tails closely replicate experimental values70 for
both pure and cholesterol-containing membrane; see Support-
ing Information, Figure S1. Despite the clear effect of
cholesterol on the membrane properties, we observe no
consistent differences in ligand binding interactions or receptor
mobility between pure POPC membrane and the cholesterol-
containing membrane. This might reflect the orexin receptors’
indifference to the membrane composition, or more likely
catching such effects would require more replicas or extended
simulation periods.
The class A GPCRs have been postulated to feature specific
cholesterol-binding sites facing the membrane milieu.55 On the
extracellular leaflet, crystal structures of GPCRs have shown
cocrystallized cholesterol molecules next to the TM3, at the
TM4−5 interface and along the ECL3-side of the receptor,
where the position at the TM6−7 interface has been most
frequently populated.55 On the intracellular leaflet, the most
notable site is the suggested “Cholesterol Consensus Motif”
(CCM)71 located at the cleft formed by the TM1−4, which
provides a binding site for one or two cholesterol molecules at
least in the β2-adrenoceptor. As these sites offer a possible
route for cholesterol-mediated effects, we sought to find and
populate them through the coarse-grained simulations. The
simulations suggested five sites on the extracellular leaflet (one
facing the TMs 1 and 7, two in the crevice formed by the
TM2−4, one close to the TM4−5 and one facing the TM6−7)
and three sites on the intracellular leaflet (two next to the TMs
1, 2, and 4, and one facing the TM3−5) (Figure 2). Many of
the sites discovered by the coarse-grained simulations match
the cholesterol binding observed in the crystal structures; both
sides of the extracellular end of the TM7, at the extracellular
TM4−5 interface, and at the intracellular TM3−5 interface.
Two cholesterol molecules were located close to the CCM site
enclosed by the TMs 1−4, but not completely within the
cavity. Of the starting sites, only the extracellular leaflet
positions on both sides of the TM7 and next to the TM4−5
were stable through equilibration, and only the two positions
flanking the TM7 were consistently stable in the production
simulations (Figure 2, Supporting Information, Figure S2).
Individual simulations show also other binding sites, most
often in the extracellular leaflet, but these are not consistent
across the pool of simulations (Supporting Information, Figure
S2). Interestingly, the TM7-flanking sites, which were the most
stable, are among those observed through X-ray crystallog-
Figure 2. Cholesterol around the receptor. In green, the initial
locations; in orange, the stable locations.
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raphy.55 Aromatic residues in the region (Phe333ECL3,
Trp3457x33, Phe3487x36, Trp3517x39, and Tyr531x31 appear to
interact with cholesterol in these “pockets”. The significance of
these sites for orexin receptor function remains to be
elucidated.
Receptor Conformation. GPCR activation is heralded by
the outswing of the intracellular end of the TM6, which is
accompanied by the reorganization of interhelical interactions
at the intracellular side of the receptor.25 The interaction
patterns have been analyzed for all GPCRs that have been
crystallized both in the active and the inactive state. The
analysis showed that there are five conserved “inactive”
interactions, which in OX2 would be Ile148
3x46−Leu3066x37,
Val751x53−Tyr3647x53 , Tyr3647x53−Phe3718x50 and
Asn3657x54−Arg3728x51.25 Similarly, there are two conserved
“active” interactions, which would be Leu3106x41−Val2405x55
and Tyr3647x53−Ile1483x46 in the OX2. In addition to these
interactions, which locate at the intracellular side of the
receptor, a triad of amino acids at the center of the receptor
has been suggested to reorganize upon receptor activation.72
This “core triad” comprises Phe3136x44, Pro2355x50 and
Val1423x40 in the OX2. During the transition from the inactive
to the active state, the side chain of Phe6x44 is suggested to pass
the side chain of the amino acid 3x40 (valine in orexin receptor
but isoleucine in adrenoceptors where the core triad
reorganization has been observed) and move closer to
Pro5x50. This movement is also tied to the outswing of the
TM6.
Our 16 simulations showed a quite static receptor (receptor
Cα RMSD of 2−4 Å in comparison to the equilibrated
structure, see Supporting Information, Figure S3). No large-
scale conformational changes were visible, including the TM6,
which retained its closed, inactive conformation. Residuewise
RMSF showed that most fluctuation took place at or near the
loop regions or chain termini (data not shown). Concerning
the reorganization of contacts upon activation, none of the
simulations showed either of the two active interactions
described above. The five interactions typical to inactive
receptors were mostly maintained, and even if they were
periodically broken, it was not caused by activation-like
conformational changes. The core triad of Phe3136x44,
Pro2355x50 and Val1423x40 remained in the starting (inactive)
conformation, except for the simulations 7 (TM7-mode) and
10 (suvorexant). The observed reorganization was not
replicated in other simulations with these ligands, and not
reflected by the large-scale conformation of the TM6, which
remained in the inactive conformation.
The antagonist-bound orexin receptor crystal structures
display three to four salt bridges lining the binding site. All
structures show the salt bridges Asp45x51−Arg6x59, Glu45x52−
His5x40, and Asp2x64−His7x38. In addition, the OX2 crystal
structures show a salt bridge between Glu2x67−Arg7x27. It has
been suggested that these bridges might stabilize the inactive
state, and that a disruption of the bridges could lead to
receptor activation.21,32 While the simulations conducted here
showed nonuniform salt bridge behavior (see Supporting
Information, Figure S4), the differences did not appear to
depend on the ligand or the membrane composition.
Peptide Binding Modes. One of the aims of our study
was to assess the stability of the two alternative orexin-A
binding modes we had previously suggested,21 called the TM5-
mode and the TM7-mode based on the orientation of the
(arbitrarily selected) H26. In the previous study, neither
binding mode was promoted by the assessment of docking
scores and interactions toward residues that had been shown
important by SDM.
While the 19-amino-acid fragment from the orexin-A C-
terminus has been shown to suffice for the biological activity,
we elected to use a full-length peptide, which we docked in the
straight α-helical conformation to replicate our previous
docking poses. The simulations, however, showed that this
straight conformation was not stable unless hydrogen bonding
between the N-terminal hook and the receptor ECL2 took
place. These hydrogen bonds often involved the ECL2 main
chain, and were not consistent across the simulations. In
absence of hydrogen bonding between the orexin-A N-
terminus and the receptor ECL2, the peptide hinge was
allowed to bend, moving the peptide N-terminus to rest
horizontally atop the receptor. This bending took place in the
simulations 2 and 5, which feature the TM5- and TM7-modes,
respectively, while other simulations with orexin-A showed the
N-terminus in contact with the ECL2, following its fluctuations
(Figure 3). Our simulations did not include the receptor N-
terminus, as its structure and location had not been resolved at
the time. The possible impact of the receptor N-terminal
helix73,74 on the peptide conformation and binding is discussed
below, after the description of the peptide C-terminus binding.
Figure 3. End point of orexin-A simulations. (A−D) TM5-mode, simulations 1−4, respectively; (E−H) TM7-mode, simulations 5−8, respectively.
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As the C-terminus of the peptide is the key for biological
activity, we focused in its stability and interactions. To assess
the stability of the predicted binding modes, we analyzed the
peptide C-terminus (N25−L33) separately, since the bending
of the hinge region and the conformational flexibility of the N-
terminal hook dominate the RMSD of the full-length peptide.
Overall, the receptor-bound C-terminus of orexin-A main-
tained its conformation and location better in the TM5-mode
(i.e., H26 side chain points toward TM5) than in the TM7-
mode, and for both binding modes, the conformation was
more stable in the pure POPC membrane than in the
cholesterol-containing membrane (Figure 4).
As the binding interaction of the peptide N-terminus are
heavily influenced by the (possible) bending of the peptide, we
assessed the binding interactions only for the peptide C-
terminus (N25−L33). These interactions, averaged across the
simulations, are shown in Figure 5, panels A and B for the
TM5- and TM7-mode, respectively. Simulationwise heatmaps
of the interaction frequencies, along with mapped interaction
energies are available in the Supporting Information as Figures
S5−S12. The stable location and conformation of the peptide
C-terminus in the TM5-mode is mirrored in well-defined,
stable interactions across simulations 1−4, whereas the higher
mobility and instability of the TM7-mode is reflected by more
variable interactions in the simulations 5−8.
As described, the orexin-A C-terminus remained quite stable
in the TM5-mode (simulations 1−4), especially in the POPC
membrane (1−2). In the cholesterol-containing membrane
(3−4), the peptide rose some 1.4 Å further from the bottom of
the binding cavity, which was reflected in the external RMSD.
In the simulation 4, the peptide C-terminus also tilted 10°
toward the TM1. Despite these differences, the interactions
remained similar in all four simulations (Figure 6). N25
interacted mainly with residues at the top of the TM7, most
often Tyr3437x31. In simulations 3 and 4, this interaction was
often a hydrogen bond; in the simulation 3, between the side
chains, either NH2···OH or OH···O, and in the simulation 4,
due to the tilting of the peptide, Tyr3437x31 OH to N24 main-
chain carbonyl. The simulation 1 showed an alternative
interaction, namely a hydrogen-π bond from N25 NH2 to
Phe3467x34. In all four simulations, the N25 also interacted
with His3507x38, either directly as seen in the simulation 1 and
2 (POPC membrane), or via a water-mediated hydrogen bond
due to the increased distance in the simulation 3 and 4
(cholesterol membrane). H26 interacted with the side chains
of the acidic residues in the ECL2 (Asp21145x51 and
Glu21245x52) in the simulations 1 and 2 (a prominent
interaction also in terms of interaction energy, as seen in
Figures S5−S6 in the Supporting Information), while the
peptide repositioning seen in the simulation 3 and 4 was
accompanied by a local tightening of the helical turn, which
brought the H26 side chain toward the ECL3. Further toward
the C-terminus, the interactions were similar in all simulations;
A28 side chain faced a pocket lined by His3507x38, Thr1112x60,
Val1142x63, and the aliphatic chain of Asp1152x64. G29 allowed
the close packing of His3507x38 against the side of the peptide
and the A28−G29 amide bond. I30 faced Met1914x65 and
Pro1313x29. To the TM2-side of the Pro1313x29 lay the L31 side
chain in a pocket lined also by Ile1303x28, Ala1102x59,
Thr1112x60, and the aliphatic chain of Gln1343x32. The T32
side chain faced Tyr3547x42, Val3537x41, His3507x38, Ile3206x51,
and Thr1112x60. Most often it hydrogen bonded intra-
molecularly to A28 (OH···O), unless the His3507x38 adopted
a rotamer where the unprotonated Nδ became available for
hydrogen bonding. This took place in the simulations 3 and 4,
where the His3507x38 side chain flipped upward to follow the
N25, in concert with the peptide movement. The L33 side
chain lay in a pocket lined by Ile3206x51, Asn3246x55, and
Figure 4. RMSD of the peptide C-terminus. In green and orange, the “external” RMSD, and in blue and red, the “internal” RMSD. (A) Simulations
1−2, (B) 3-4, (C) 5−6, and (D) 7−8. See Methods, Analysis, for definitions for the external and internal RMSD.
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Phe2275x43. The NH2 of the amidated C-terminus mainly
bonded to the G29 or the I30 carbonyl. An interesting network
of interactions took place at the bottom of the binding cavity,
between the exposed carbonyls of L31 and T32, along with
Gln1343x32 and Tyr3176x48. In the beginning of the simulations,
Gln1343x32 side-chain nitrogen usually formed a hydrogen
bond to the carbonyl of T32, while Tyr3176x48 hydroxyl
pointed down. This was most likely imposed by the starting
configuration. During the simulations, the Gln1343x32 hydrogen
bond shifted to the carbonyl of L31, Tyr3176x48 hydroxyl
flipped upward, and a water molecule moved in to bridge
interactions between the Gln1343x32 side-chain carbonyl,
Figure 5. Heatmap of binding interactions of the peptide C-terminus, averaged across all simulations sharing the same binding mode (1−4 for
TM5-mode, 5−8 for TM7-mode). The heatmaps display the fraction of simulation time that any interatomic distance was below 4 Å. H:xx denotes
the presence of a hydrogen bond and W:xx the presence of a water-mediated hydrogen bond. These are shown only when the frequency was over
20%.
Figure 6. Orexin-A binding interactions in the TM5-mode. (A) Binding site with close receptor residues shown as sticks. (B) Hydrogen bonds
between the peptide C-terminus and the receptor. The atomic coordinates for the TM5-mode receptor complex presented here are available as
Supporting Information.
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Tyr3176x48 hydroxyl and the T32 carbonyl. The Gln3x32−L31
interaction was also prominent in terms of interaction energy
(Figures S5−S8 in Supporting Information). In the simulation
2, this reorganization did not happen, as Tyr3176x48 hydroxyl
immediately bound to the Gln1343x32 side-chain carbonyl,
leaving no space for the bridging water molecule. While the
hydroxyl of the Tyr3547x42 was consistently close to the
carbonyl of L31, it participated in the network only transiently,
preferring to bind with Thr1112x60; this interaction was almost
exclusively seen only in the TM5-mode (simulations 1−4).
The carbonyl of L33 also took part only rarely.
The instability of the orexin-A helix in the TM7-mode
rendered it difficult to sum up the interactions across the
simulations 5−8. The simulation 7 showed an almost complete
“melting” of the peptide C-terminus, and in simulation 6 and 8
the hinge region unfolded and fell into the cavity between the
TMs 2 and 7. The common observations between the
simulations were that N25 was close to Asp21145x51 and
Cys21045x50, I30 inhabited a pocket lined by Ile3206x51,
Asn3246x55, Lys3276x58, and Phe3467x34, and L33 was close to
His3507x38, often hydrogen bonded to the C-terminal amide. In
terms of interaction energy, there was no apparent consistency
between the simulations (Supporting Information, Figures S9−
S12). The simulation 7 with the most prominent peptide
unfolding aside, the three other simulations (5, 6, and 8)
showed the side chain of A27 facing a salt bridge formed by
Glu21245x52 and Arg3286x59, A28 residing under the ECL2 and
the side chain of L31 facing the pocket of Pro1313x29,
Thr1353x33, Gln1874x61 and Met1914x65. The C-terminal
carbonyls did not form uniform interactions such as those
described above for the TM5-mode.
Given the difference in stability, in terms of both peptide
conformation and binding interactions, between the TM5- and
the TM7-mode of binding, the TM7-mode seems less likely to
be the correct binding mode. Therefore, if the C-terminus of
the orexin-A indeed binds in an α-helical conformation, we
suggest the TM5-mode as the binding mode for orexin-A at
the OX2. The binding mode should also be valid for the OX1
receptor and for orexin-B, since the orexin peptide C-terminus
is conserved and the receptor structures are similar. However,
with current data, we cannot rule out the possibility of
nonhelical bioactive conformation. Endothelin, for example,
adopts a conformation that is mostly helical but the C-
terminus is extended into the receptor cavity.75 On the other
hand, endothelin displays a similar extended C-terminus also in
solution,76 whereas orexin peptides show consistently helices
also at the peptide C-terminus.
Concerning the receptor amino acids that SDM studies have
shown to be important for orexin-A binding and/or receptor
activation,14,15 the peptide C-terminus in the TM5-mode
interacts strongly with Thr1112x60, Gln1343x32, and His3507x38,
comes into direct close contact with Phe2275x43, Asn3246x55
and Tyr3547x42 and forms water-bridged interactions to
Tyr3176x48. Thr1112x60 and Tyr3547x42 are also consistently
hydrogen bonded with each other. Asp21145x51 and Glu21245x52
in the ECL2 interact with the middle section of the orexin-A,
but defined binding partners cannot be summarized from the
simulations as the peptide flexibility results in quite different
midsection conformations and locations. Trp214 in the ECL2
and Tyr2235x39 line the binding pocket at the ECL2−TM5
junction, but the peptide does not interact with them in our
simulations. However, both pack between the TMs 4 and 5,
which suggest that they might contribute to the receptor
overall conformation or the binding site conformation.
Thr2315x461 and Tyr2325x47 are mostly out of reach for the
peptide, especially as Tyr2325x47 mostly resides between the
TMs 5 and 6. There are also no frequent water-mediated
interactions with the peptide, but the residues could be a part
of the hydrogen-bond network at the bottom of the binding
site or otherwise important for the activation cascade.
The conformations of the bound peptide in the TM5-mode
simulations reflect the NMR-derived models of the con-
formation in water; the peptide C-terminus and the middle
section retain their helical conformation, while the hinge
region allows the peptide to bend. However, in the simulation
2, and to some extent also in the simulation 3, the peptide
bends toward the TM5, which is not among the bending
directions observed in the NMR models of orexin-A.11,12 The
direction is similar to the orexin-B solution structure,13 except
that the bending takes place one helical turn further from the
C-terminus. Recent studies73,74 have been able to resolve the
structure of the OX1 and OX2 N-terminus, which appears to
form a short amphipathic helix either atop the receptor or
pointing away from the receptor, residing atop the membrane.
While it remains unclear whether these different locations
represent different functional states or if either one is a
crystallization artifact, the N-terminal helix was shown, through
mutagenesis, to be important in the peptide-induced receptor
activation.73 This suggests direct interaction with the peptide,
which in turn would promote the location next to the ECL2. If
the N-terminal helix would indeed lie atop the receptor in
interaction with ECL2, as seen in the OX1 structure,
73 it would
prevent the binding of orexin-A in the straight α-helical
conformation such as the one we used for docking and as the
starting conformation for the simulations. However, the
peptide bent toward the TM5 would fit snugly underneath
the N-terminal helix, presenting R15 and Y17 among others
toward the downward-facing polar residues of the N-terminal
helix (Figure 7). Interestingly though, the N-terminal helix in
the crystal structure features lipophilic residues (Phe31, Leu32,
Tyr34, Leu35, and Trp36) facing toward the solvent, which
seems unfavorable. A roll of 180° would bring them in contact
with L16, Y17 and L20 in the orexin-A. It is also possible that
the N-terminal helix adopts a distinct peptide-bound
Figure 7. Simulation-derived bent conformation of orexin-A overlaid
with the recently published OX1 structure, which displays the N-
terminal receptor helix.
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conformation, which differs from the small-molecule-bound
structures.
Small Molecule Binding. In addition to orexin-A, we
carried out simulations with bound small molecules, the
antagonist suvorexant (simulations 9−10) and the agonist
Nag26 (simulations 11−14). Suvorexant binding mode seen in
the crystal structures was stable through the simulations in
both membranes. The external RMSD fluctuated around 1 Å,
and the internal RMSD between 0.5−1 Å (Figure 8). The
chlorinated benzoxazole remained in the pocket lined by
Cys1072x56, Ala1102x59, Thr1112x60, Val1142x63, Trp12023x50,
Ile1303x28, Pro1313x29, and Gln1343x32, with the oxazole ring
Figure 8. RMSD of the small molecular ligands. In green and orange, the “external” RMSD, and in blue and red, the “internal” RMSD.
Figure 9. Heatmap of binding interactions of the small molecular ligands. For the mapping, the small molecules were divided into groups as
displayed below the heatmaps. The heatmaps display the fraction of simulation time that any interatomic distance was below 4 Å. H:xx denotes the
presence of a hydrogen bond and W:xx the presence of a water-mediated hydrogen bond. These are shown only when the frequency was over 20%.
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packing next to Pro1313x29 (Figure 9A). A water molecule was
often seen binding with the oxazole nitrogen, but it did not
form a stable water-mediated interaction. The seven-
membered ring occupies a central location with the methyl
facing Phe2275x43. The linker carbonyl hydrogen bonds to
Asn3246x55 and via water to His3507x38. The methylated
benzene ring interacts with His3507x38, Val3537x41, and
Tyr3547x42 in TM7, and is flanked by Gln1343x32 and the
benzoxazole ring on the other side. Underneath, the
Gln1343x32−Tyr3547x42 hydrogen bond is maintained through-
out the simulations, which is not seen consistently in any other
simulations. The triazole ring is next to Ile3206x51 and
Phe2275x43, and traps 2−3 water molecules into a pocket
between the TMs 5 and 6, where the water molecules form a
hydrogen-bond network between Ser3216x52, Thr2315x461, and
His2245x40.
Concerning the pool of crystallized orexin receptor
antagonists, the binding mode of suvorexant is near identical
between the OX1 and OX2 subtypes,
32,73 and closely replicated
by the OX1-selective SB-674042.
73 The OX2-selective EMPA
also occupies a similar location and displays a horseshoe-like
conformation.74 All antagonists display the intact Gln3x32−
Tyr7x42 hydrogen bond in the crystal structures.
The small molecular agonist Nag26 was more mobile than
suvorexant both in terms of conformation (internal RMSD
1.5−3 Å) and location (external RMSD 3−6 Å)(Figure 8),
which is not surprising given the number of rotatable bonds in
the ligand scaffold. While the molecule mostly retained the
initial location, especially the extremities (groups Na1−2 and
Na8−9 in Figure 9), showed significant movement. This was
reflected in the interaction patterns, which were not always
consistent between simulations. The average binding inter-
actions are shown in Figure 9B, and the interaction heatmaps
for individual simulations, along with interaction energies, are
available in Supporting Information as Figures S13−S18. In
some simulations, the ligand retained its initial horseshoe-
packed conformation, whereas in others, the ligand extended
within the binding site (Figure 10). The dimethylamide group
was initially located deep in the binding cavity, next to
Thr2315x461 and flanked by Tyr3176x48, Val1383x36, and
Ser3216x52. At this site, the carbonyl oxygen often formed a
water-mediated hydrogen bond with the side chain of
Thr2315x461. In the simulations 13 and 14 (cholesterol
membrane), the group retained this position, whereas in the
simulations 11 and 12, the group rose a bit and then pushed
in-between the TMs 4 and 5. This rise brought the amide
oxygen in water-mediated contact with Asn3246x55 or
Arg3286x59. The push also moved Thr2315x461 and Phe2275x43
toward the TM4, resulting in a marked counterclockwise
rotation of the upper section of the TM5 and tightening of the
helical turn at the bulge near Tyr2325x47. The sulfonamide
moiety, which is crucial for activity,7 lay next to Pro1313x29 in
all simulations but found different binding partners. In the
simulation 13, where the Nag26 conformation was the most
stable, the sulfonamide formed both direct and water-bridged
hydrogen bonds from the oxygens to Gln1343x32. Despite close
proximity, Gln1874x61 and Thr1353x33 did not hydrogen bond
with the sulfonamide. The amide nitrogen formed a stable
water-bridge to Glu21245x52, which in turn remained bonded to
Arg3286x59 through the simulation. The simulation 11 showed
a more mobile sulfonamide moiety, which hydrogen-bonded
first with Arg3286x59 and then moved higher and toward the
center of the binding site and switched to Lys3276x58. This
movement also allowed the amide nitrogen to bond with
Asp21145x51. Arg3286x59 and Glu21245x52 remained in inter-
action through the simulation, but the ligand movement
moved both side chains toward the TM5 and appeared to
constrict the entrance of the binding site. Simulations 12 and
14 showed Arg3286x59 hydrogen bonding with the sulfonamide
and Glu21245x52/Asp21145x51, while the amide nitrogen
interacted with Cys21045x50 main-chain oxygen via water.
Water also bridged transient interactions between the
sulfonamide oxygens and the side chains of Asp21145x51 and
Glu21245x52. The hydrogen bonding between the sulfonamide
nitrogen and Lys3276x58/Arg3286x59 seen in simulations 11, 12
and 14 was also a strong contributor to the interaction energy
(Supporting Information, Figures S13, S14, and S16). The rest
of the molecule was quite mobile; if the ligand retained or
readopted the packed conformation, the methylated ring
folded in-between the TM7 and the rest of the ligand, favoring
interactions with Phe3467x34. In the case of ligand extension,
the ring moved close to the ECL1, which brought the polar
atoms of the chain linker in hydrogen-bonding distance of the
exposed carbonyl of Cys21045x50, and also Thr1112x60.
It is noteworthy that we employed only one starting
conformation for the Nag26 agonist. As also our peptide
simulations highlighted, the starting conformation can heavily
impact the simulation trajectory, and it is possible that another
starting conformation for the Nag26 would have yielded
different results. Then again, our simulations showed the
Nag26 sampling multiple conformations within the binding
site, unable to find a markedly stable binding mode. This could
mirror the weaker binding interactions in comparison to
suvorexant; the Nag26 Ki is 140 nM at the OX2, while the
corresponding value for suvorexant is 0.35 nM.2,7 Alternatively,
the initial conformation might be far from correct, but given
the resemblance between our docking pose and the structurally
related small molecular antagonist EMPA (not shown), that
seems unlikely.
Water Molecules. The simulations showed distinct
preferences for water molecule locations. Within the receptor
core, Asp1002x50 was often accompanied by few water
molecules (Figure 11). In some simulations, a semistable
chain of water molecules connected these waters to the binding
cavity. Two to three water molecules usually resided between
the TMs 5 and 6, bound to Thr2315x461 and Ser3216x52,
sometimes also to His2245x40 and Asn3246x55. Often, the
Figure 10. Small molecular agonist Nag26 was mobile during the
simulations, rendering the binding mode identification difficult.
Representatives of the three most visited conformations are shown.
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simulations showed also stable water molecules that took part
in the ligand−receptor interactions; these were discussed in
detail above for each complex.
Many of the observed stable water molecules are also
present in the high-resolution crystal structures,32,73,74 such as
between the TMs 5 and 6 (Thr2315x461 and Ser3216x52),
around Asp1002x50, at the TM6 kink and atop the TM6, and in
the intracellular cavity between TMs 3, 4, and 5. Water
molecules were also seen around the ECL2 in matching
positions to the crystal structures, and close to the TMs 5 and
6. Interestingly, the water molecule that takes part in
suvorexant binding, bridging the carbonyl oxygen to
His3507x38, was also stable in simulation 1 (orexin-A in the
TM5-mode), where the water molecule bridged a three-way
interaction between Asn3246x55, His3507x38 and the main-chain
carbonyl of N25. In simulation 13, the carbonyl oxygen in the
linker chain of the Nag26 occupied a similar position. The
water molecules between the TMs 5 and 6 provide the most
interesting case; there were two-to-three water molecules in all
simulations, unless the TM5 made the counterclockwise turn,
moving Thr2315x461 further from Ser3216x52 and thus breaking
the water-binding pocket. With the Nag26 simulations, this
was linked with the dimethylamide pushing between the TMs
4 and 5, but in the simulation 2 (orexin-A in the TM5-mode),
this turning appeared to take place without clearly defined
ligand-dependency.
Activation. The activation of a GPCR is a chain of events
propagating through the receptor from the ligand-binding site
to the G-protein-binding site at the intracellular face. In our
simulations, the intracellular conformation of the receptor
remained in the inactive state, as anticipated, which was
mirrored by the absence of the common contacts observed in
the structures of activated GPCRs.25 Concerning the transi-
tional steps along the activation cascade, the core triad,72
which lies underneath the binding site and is thought to be
relevant in relaying the activation signal, also remains in the
initial, inactive conformation.72 It is noteworthy that orexin
receptors have a valine residue at 3x40, whereas a bulkier
residue such as isoleucine is often found in the receptors that
display a clear “activation” of the core triad. The M2 receptor
also features Val3x40, but there both active77 and inactive78
receptor structure resemble the activated core triad of e.g. β2
receptor. At the binding site, the activation determinants differ
between receptors, rendering comparison of orexin receptors
to the available structures of active GPCRs dubious. However,
a common theme in activating interactions is a change in
interhelical interactions across the binding site. With this in
mind, we noted that suvorexant simulations showed a
consistent hydrogen bond between Gln1343x32 and
Tyr3547x42, which was not seen in other simulations, but is
replicated by other crystallized antagonists.73,74 In contrast, the
simulations with orexin-A in the TM5-mode showed this
hydrogen bond only 0−8% of the simulation time. On the
other hand, the TM5-mode propagated Tyr3547x42−
Thr1112x60 hydrogen bonding. We speculate that enforcing
the Gln1343x32−Tyr3547x42 hydrogen bond could stabilize the
inactive state of the receptor, and that the alternative
Tyr3547x42−Thr1112x60 hydrogen bond could enable receptor
activation, even though Nag26 did not show as strong effect as
the orexin peptide did. The comparison between suvorexant
and Nag26 highlights the agonist interacting with Thr2315x461,
a location which is central to the activation of adrenoceptors,
for example. The Nag26 also interacted with the ECL2, and
the salt bridge Glu21245x52−Arg3286x59, which crosses the
Figure 11. Several water molecules remain in the binding site throughout the simulations. (A) Overview of the binding-site water. The circles with
lowercase letters refer to the panels on the right. (B) TM5−6 interface. (C) TM4−5 interface. (D) Asp1002x50.
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binding site. One could speculate that this interaction with the
salt bridge could induce an inward tilt of the extracellular end
of the TM6, which, in turn, could pivot the TM6 and open the
intracellular binding site. Nag26 was also seen in two
simulations pushing between the TMs 4 and 5, which induced
a tightening in the TM5 helix and changed the interactions
between the TMs 4, 5, and 6. This could also serve in
destabilizing the inactive receptor conformation, thus facilitat-
ing receptor activation.
■ CONCLUSIONS
We performed extensive molecular dynamics simulations on
the OX2 receptor. On the basis of the simulations, we suggest
that orexin-A binds the receptor in a configuration where N25
faces the TM7 (Tyr3437x31), H26 points toward the TM5 but
interacts either with the ECL2 or the ECL3, A27 faces the
ECL1, A28 and G29 pack next to His3507x38, I30 and L31
flank the TM3 and Pro1313x29 with the L31 side chain
occupying a pocked beneath the ICL1, T32 faces the TM7 and
L33 the TMs 5 and 6. The exposed carbonyls in the last helical
turn participate in a hydrogen-bonding network formed by a
stable water molecule, Gln1343x32 and Tyr3176x48. The peptide
N-terminus interacts with the ECL2 hairpin, if extended, or
bends toward the TM5 to lie atop the binding site. The
presented binding mode is, however, contingent on the
assumption that the bioactive conformation of the orexin
peptide C-terminus is helical and not unfolded.
The small molecule simulations highlight the stability of
suvorexant binding, and the contrasting flexibility of the Nag26
agonist. The antagonist and agonist have such different
interactions patterns that it is difficult to identify definite key
interactions for agonism or antagonism, but certain differences
arise, such as the suvorexant-induced stabilization of
Gln1343x32−Tyr3547x42 hydrogen bond and the binding
interactions of Nag26 toward Thr2315x461, Tyr3176x48, and
the ECL2 amino acids Cys21045x50, Asp21145x51, and
Glu21245x52. Nag26 is also observed pushing the extracellular
end of the TM5 into a counterclockwise rotation, which
influences the interhelical interactions between the TMs 4, 5,
and 6, for example, breaking up a water-binding site.
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(53) Kucěrka, N.; Nieh, M.-P.; Katsaras, J. Fluid Phase Lipid Areas
and Bilayer Thicknesses of Commonly Used Phosphatidylcholines as
a Function of Temperature. Biochim. Biophys. Acta, Biomembr. 2011,
1808, 2761−2771.
(54) Pabst, G.; Rappolt, M.; Amenitsch, H.; Laggner, P. Structural
Information from Multilamellar Liposomes at Full Hydration: Full q-
Range Fitting with High Quality x-Ray Data. Phys. Rev. E: Stat. Phys.,
Plasmas, Fluids, Relat. Interdiscip. Top. 2000, 62, 4000−4009.
(55) Gimpl, G. Interaction of G Protein Coupled Receptors and
Cholesterol. Chem. Phys. Lipids 2016, 199, 61−73.
(56) Marrink, S. J.; Risselada, H. J.; Yefimov, S.; Tieleman, D. P.; de
Vries, A. H. The MARTINI Force Field: Coarse Grained Model for
Biomolecular Simulations. J. Phys. Chem. B 2007, 111, 7812−7824.
(57) Qi, Y.; Ingoĺfsson, H. I.; Cheng, X.; Lee, J.; Marrink, S. J.; Im,
W. CHARMM-GUI Martini Maker for Coarse-Grained Simulations
with the Martini Force Field. J. Chem. Theory Comput. 2015, 11,
4486−4494.
(58) Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis,
J. L.; Dror, R. O.; Shaw, D. E. Improved Side-Chain Torsion
Potentials for the Amber ff99SB Protein Force Field. Proteins: Struct.,
Funct., Genet. 2010, 78, 1950−1958.
(59) Jam̈beck, J. P. M.; Lyubartsev, A. P. Another Piece of the
Membrane Puzzle: Extending Slipids Further. J. Chem. Theory
Comput. 2013, 9, 774−784.
(60) Rackers, J. A.; Wang, Z.; Lu, C.; Laury, M. L.; Lagarder̀e, L.;
Schnieders, M. J.; Piquemal, J.-P.; Ren, P.; Ponder, J. W. Tinker 8:
Software Tools for Molecular Design. J. Chem. Theory Comput. 2018,
14, 5273−5289.
(61) Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.;
Cerutti, D. S.; Cheatham, T. E.; Darden, T. A.; Duke, R. E.; Gohlke,
H.; et al. Amber 14; University of California: San Francisco, CA, 2014.
(62) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.;
Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci,
B.; Petersson, G. A.; et al. Gaussian 09, Revision E.01; Gaussian, Inc.:
Wallingford, CT, 2009.
(63) Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W.
L. Evaluation and Reparametrization of the OPLS-AA Force Field for
Proteins via Comparison with Accurate Quantum Chemical
Calculations on Peptides. J. Phys. Chem. B 2001, 105, 6474−6487.
(64) Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, Efficient Generation
of High-Quality Atomic Charges. AM1-BCC Model: II. Parameter-
ization and Validation. J. Comput. Chem. 2002, 23, 1623−1641.
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